YuanSheng Ventures
元生创投
YuanSheng Ventures (元生创投) shows up in elsewhere's corpus almost exclusively as a life-sciences investor, usually alongside other healthcare-focused funds — the material doesn't include a standalone profile with its founding date or fund size. Its recent activity is dense: it co-led 演生潮's hundreds-of-millions-yuan Pre-A round with Qiming Venture Partners in August 2025 , joined AusperBio's $63M Series B2 co-led by Qiming in September 2025 , and followed into AllinkBio's $42M Series A led by Linear Capital . Going back further, it led rounds for Pulnovo Medical , neoX Biotech , and Nutshell Therapeutics' $40M Series A+ , and co-invested in stem-cell company Shize Biotech's angel round back in 2021 . The pattern across these deals — bispecific antibodies, ADCs, stem cells, medical devices — is a fund squarely in innovative biotech, often co-investing with Qiming, Legend, and Lilly Asia Ventures-type peers, though elsewhere's corpus doesn't cover the fund's own history or team.
AI-generated — may contain errors, please verify.
Coverage
Inno Pharmaceuticals Completes Nearly RMB 800 Million Series D Funding to Accelerate Global Multicenter Clinical Development of Precision Targeted Drugs
The company has pioneered a proprietary active-targeting liposomal drug delivery platform, underpinning an innovative drug pipeline that spans multiple serious disease areas, including cardiovascular and cerebrovascular diseases and glioblastoma.
Rhinovate Raises Pre-A Funding to Accelerate High-Performance Materials R&D With Self-Evolving Physical AI | Unity Ventures Portfolio
Building Reusable AI Infrastructure for Materials R&D
VAST Nears $200 Million in Series A Funding, Unveils World Model in Parallel | Oasis Vitality
Project Eden: A General World Model Research Initiative
5Y News｜Aikelian Biotechnology Completes $68.7 Million Funding Round
Aikelian Biotech has successfully completed an oversubscribed $68.7 million funding round.
AllinkBio Closes Nearly $50 Million Series A Extension, BlueRun Ventures Continues to Double Down | BlueRun Family
Accelerating Clinical Development at Full Speed
AusperBio raises $63M in Series B2 funding co-led by Qiming Venture Partners
Haibo Pharmaceutical is a clinical-stage innovative drug company focused on the R&D of self-developed targeted small nucleic acid therapeutics, with "achieving clinical cure for chronic hepatitis B" as its core mission.
Evolutionary Tide Raises Hundreds of Millions of Yuan in Pre-A Round, Qiming Venture Partners Co-Leads
Emergent Tide is built on original research from the Tsinghua University School of Medicine team in the field of humoral immunity, developing novel therapeutics for inflammatory and autoimmune diseases against a first-in-class global target, addressing core challenges in the field and significant unmet clinical needs.
Gaorong Report · 2025 | Innovative Drugs, Agri-Tech, AI Content Platforms Close Funding Rounds; Gaorong Earns Multiple Accolades
Innovation as the sail, hard work as the oar.
Anlink Bio Completes $42 Million Series A Round to Accelerate Global Development of Bispecific Antibodies and ADC Pipeline
Achieving a rapid transition from preclinical to clinical stages.
BlueRun Ventures Leads AllinkBio's $42 Million Series A Round | BlueRun Ventures
Accelerating Global Development of Bispecific Antibodies and ADC Products
Pulnovo Medical Closes New Tens-of-Millions USD Funding Round to Accelerate Global Expansion
It secured a foothold in global markets and made substantial headway on multiple fronts in 2022.
The worse the market gets, the more GPs want LPs to have the guts to deploy capital.
GPs need to buckle down and get the work done — happily.
Source Code Capital Portfolio | Nutshell Therapeutics Announces $40 Million Series A+ Round, Existing Shareholder Source Code Capital Continues to Increase Stake
Advance the conformation-based drug discovery platform and innovative pipeline across all fronts
3 Biopharma Companies Raise Over 1 Billion Yuan Combined | FreeS Family Funding News · October–November
Firmly bullish on the development of biomedical innovation in China
7 Companies Raised Nearly 1.5 Billion Yuan, 4 Valued Above 1 Billion Yuan | FreeS Family Funding News · September
Every step of growth for an innovative company: from 0 to 1, from 1 to 10, and from 10 to 100
As Fierce as August | 5Y News Monthly
The big news from last month.
FreeS Family Funding News · June | Saturnbird, Shize Biotech, and Light Travel Secure Funding
We also released two short videos this week — follow us to check them out.
5Y News | Neox Biotech Completes Tens of Millions of Dollars in Series A+ Funding to Advance Innovative Drug Pipeline
5Y Capital continues to provide support.
FreeS Family Funding News · May | Chicecream, ACC Super Accessories, DataPipeline, and Ganying AI Secure Funding
We also released two short videos this week — follow us to check them out.
April, When All Things Grow | 5Y News Monthly
Looking back at last month's big events, ready to take on Q2 with full confidence.
5Y News | Aromatherapy skincare brand *Zhuben* closes two rounds totaling $50 million in funding
A holistic wellness brand that embraces the philosophy of "less is more."
Source Code Capital portfolio company Kaishan announced the completion of a 100 million RMB Series B funding round, with existing investor Source Code Capital continuing to increase its stake.
Kaishan developed its proprietary "Jingxiang" (pure aroma) baijiu, becoming the first company to successfully establish a new aroma-type industry standard.
